Intravascular ultrasound (IVUS) developer Endosonics of Pleasanton,CA, has extended its product distribution relationship with Cordis.The deal gives Cordis, of Miami Lake, FL, exclusive distributionrights in North America and Europe to Endosonics IVUS
Intravascular ultrasound (IVUS) developer Endosonics of Pleasanton,CA, has extended its product distribution relationship with Cordis.The deal gives Cordis, of Miami Lake, FL, exclusive distributionrights in North America and Europe to Endosonics IVUS productsfor coronary applications. Cordis has agreed to provide fundingfor joint product development programs and made a $5 million equityinvestment in Endosonics.
Endosonics in January reported year-end financial results thatshowed revenues more than doubling, to $17.1 million from $8 millionin 1994. Its loss for the year narrowed, to $10.5 million comparedwith $13.3 million in 1994.
New Study Assesses Long-Term Outcomes of PSMA PET Use in PCa Recurrence Cases
October 24th 2024For patients with biochemical recurrence of prostate cancer, PSMA PET imaging may facilitate a 12.8 percent lower incidence of prostate cancer mortality in contrast to the combination of CT and bone scan, according to long-term outcome estimates from a new decision-analytic modeling study.
Can Diffusion MRI Predict Patient Response to Neoadjuvant Chemotherapy for Breast Cancer?
October 23rd 2024A model emphasizing time-dependent diffusion MRI was 15 percent more effective than apparent diffusion coefficient (ADC) measurements at predicting pathologic complete response to neoadjuvant chemotherapy for women with breast cancer, according to new research.